Celcuity LLC (CELC NASDAQ) stock market data APIs
$73.8018
0.02(0%)
as of November 7, 2025
Try our APIs with
free plan!
Celcuity LLC Financial Data Overview
Price chart is built with
Anychart
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Prev. Close
73.8018
Open
73.8198
High
74.838
Low
71.462
52 wk Range
7.575-83
Market Cap
3 148 M
Shares Outstanding
42 427 K
EPS
-1.04
Beta
0.24
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Celcuity LLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Celcuity LLC data using free add-ons & libraries
Get Celcuity LLC Fundamental Data
Celcuity LLC Fundamental data includes:
- Net Revenue:
- EBITDA: -146 486 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.88
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celcuity LLC News
New
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year.
Celcuity hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534% this year. Continue Reading View Comments
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it w...
Insider-Favored Growth Stocks To Consider In October 2025
As of late October 2025, major U.S. stock indexes have reached new record highs, buoyed by solid corporate earnings and optimism surrounding potential trade agreements between the U.S. and China. Amid...
Stocks Rally on Easing Trade Tensions and Solid Q3 Earnings
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.07%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +1.12%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.30%. December E-min...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
